On a deal spree, Take­da grabs Japan­ese cabo rights in $145M pact with Ex­elix­is

A deal-hun­gry Take­da has stepped up with a $145 mil­lion pact to part­ner with Ex­elix­is on cabozan­ti­nib.

Ex­elix­is $EX­EL grabbed a $50 mil­lion up­front in the deal, and stands to earn an­oth­er $95 mil­lion in mile­stones, as Take­da takes a lead role in de­vel­op­ing cabo for the Japan­ese mar­ket.

“We in­tend to pur­sue reg­u­la­to­ry ap­proval for (re­nal cell car­ci­no­ma) in­di­ca­tions as soon as we’re able, and look for­ward to com­menc­ing the lo­cal clin­i­cal tri­al pro­gram to fur­ther strength­en the clin­i­cal pro­file of cabozan­ti­nib,” said Tsu­doi Miyoshi, head of Japan On­col­o­gy Busi­ness Unit of Take­da.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.